false
0002032545
0002032545
2026-11-10
2026-11-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): November 10, 2026
| Callan
JMB Inc. |
| (Exact
name of registrant as specified in its charter) |
| Nevada |
|
001-42506 |
|
99-0931141 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
244
Flightline Drive
Spring
Branch, Texas |
|
78070 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (830) 438-0395
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.001 par value |
|
CJMB |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
1.01. Entry into a Material Definitive Agreement.
On
November 10, 2026, Callan JMB Inc., a Nevada corporation (the “Company”), entered into a Securities Purchase Agreement
(the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which
the Company agreed to issue and sell to the Purchasers, in a private placement (the “Private Placement”), an aggregate
of 1,363,639 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common
Stock”), at a purchase price of $1.10 per share, for aggregate gross proceeds of approximately $1.5 million, before deducting
placement agent fees and other offering expenses. The Purchase Agreement permits the sale of up to an aggregate of $3,000,000 of Shares.
The
Purchasers include Wayne Williams, the Company’s Chairman, President and Chief Executive Officer, who purchased 363,637 Shares
for an aggregate purchase price of $400,000.70, and persons affiliated with Mr. Williams and other insiders of the Company, who purchased
an aggregate of 1,000,002 Shares. The Private Placement was approved by the Company’s Board of Directors, with Mr. Williams having
disclosed his interest in the transaction.
The
closing of the Private Placement occurred on November 10, 2026. The Company intends to use the net proceeds derived from the Private
Placement for strategic growth initiatives and for other corporate purposes.
The
Purchase Agreement contains customary representations, warranties and covenants of the Company and the Purchasers, and provides for indemnification
of the Purchasers by the Company. The Shares are unregistered securities and will bear a restrictive legend.
The
representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of the Purchase Agreement and
as of specific dates, were solely for the benefit of the parties to the Purchase Agreement and may be subject to limitations agreed upon
by the contracting parties.
Alexander Capital, L.P. (the “Placement
Agent”) acted as exclusive placement agent for the Private Placement on a reasonable best efforts basis pursuant to a Placement
Agency Agreement, dated November 10, 2026, between the Company and the Placement Agent (the “Placement Agency Agreement”).
Pursuant to the Placement Agency Agreement, the Company paid the Placement Agent a cash fee equal to 6.0% of the aggregate gross proceeds
of the Private Placement, reimbursed the Placement Agent for certain expenses up to $35,000, and issued to the Placement Agent, or
its designees, warrants (the “Placement Agent Warrants”) to purchase up to 54,546 shares of Common
Stock (the “Warrant Shares”), representing 4.0% of the Shares sold in the Private Placement, at an exercise price
of $1.10 per share. The Placement Agent Warrants are exercisable immediately and expires five years from the commencement of sales
in the Private Placement. The Placement Agency Agreement contains customary representations, warranties, indemnification and contribution
obligations.
The
foregoing descriptions of the Purchase Agreement, the Placement Agency Agreement and the Placement Agent Warrant do not purport to be
complete and are qualified in their entirety by reference to the full text of the Purchase Agreement, the Placement Agency Agreement
and the form of Placement Agent Warrant, copies of which are filed as Exhibits 10.1, 10.2 and 4.1, respectively, to this Current Report
on Form 8-K and are incorporated by reference herein.
This
Current Report shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall such securities be offered or
sold in the United States absent registration or an applicable exemption from the registration requirements and certificates evidencing
such shares contain a legend stating the same.
Item
3.02 Unregistered Sales of Equity Securities.
The
information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. The Shares and
the Placement Agent Warrant (and the Warrant Shares) are being offered and sold in reliance on the exemption from registration provided
by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation
D promulgated thereunder, based in part on representations that each Purchaser is an “accredited investor” as defined in
Rule 501(a) of Regulation D and is acquiring the securities for investment purposes. No general solicitation was used in connection with
the offer or sale of such securities. Such securities have not been registered under the Securities Act and may not be offered or sold
in the United States absent registration or an applicable exemption from registration requirements.
Item
8.01 Other Events.
On
November 12, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is filed as Exhibit
99.1 to this Current Report on Form 8-K.
Forward-Looking
Statements
This
Report and the exhibit(s) attached hereto, including the disclosures set forth herein, contain certain forward-looking statements that
involve substantial risks and uncertainties. When used herein, the terms “intends,” “anticipates,” “expects,”
“estimates,” “believes” and similar expressions, as they relate to us or our management, are intended to identify
such forward-looking statements.
Forward-looking
statements in this Report or hereafter, including in other publicly available documents filed with the Commission, reports to the stockholders
of the Company and other publicly available statements issued or released by the Company involve known and unknown risks, uncertainties
and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ
from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements.
Such future results are based upon management’s best estimates based upon current conditions and the most recent results of operations.
These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Commission, each of
which could adversely affect the Company’s business and the accuracy of the forward-looking statements contained herein. The Company’s
actual results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements.
The Company expressly disclaims any obligation or intention to update these forward-looking statements contained in this Report.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
The
following exhibits are being filed herewith:
| Exhibit
No. |
|
Description |
| 4.1 |
|
Form of Placement Agent Warrant |
| 10.1 |
|
Securities Purchase Agreement, dated as of November 10, 2026, by and between Callan JMB Inc. and the purchasers named therein* |
| 10.2 |
|
Placement Agency Agreement, dated November 10, 2026, by and between Callan JMB Inc. and Alexander Capital, L.P. |
| 99.1 |
|
Press Release dated November 12, 2026 |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
*
Certain personal information of the Purchasers has been omitted pursuant to Item 601(a)(6) of Regulation S-K.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date:
November 13, 2026 |
Callan
JMB Inc. |
| |
|
|
| |
By: |
/s/
Wayne Williams |
| |
Name: |
Wayne
Williams |
| |
Title: |
Chief
Executive Officer |
Exhibit
99.1
Callan
JMB CEO and Management Team Invest $1.5 Million in Common-Only Transaction at a Premium of $1.10 Per Share, Reinforcing Confidence in
Growth Strategy
SPRING
BRANCH, Texas, Nov. 12, 2026 (GLOBE NEWSWIRE) — Callan JMB Inc. (NASDAQ: CJMB) (“Callan JMB” or the “Company”),
a provider of logistics, emergency preparedness, and critical supply chain solutions for the healthcare industry and government organizations,
today announced that CEO Wayne Williams and members of its executive leadership team have invested $1.5 million personally through the
purchase of common stock at a premium of $1.10 per share.
The
investment underscores management’s conviction in Callan JMB’s strategic direction, operational progress, and short- and
long-term growth opportunities.
“Our
leadership team is putting its own capital to work because we believe in the path ahead,” said Wayne Williams, Chief Executive
Officer of Callan JMB. “This is a direct expression of our confidence in the Company’s strategy, and our commitment to building
value alongside shareholders.”
The
investment arrives as Callan JMB has recently completed multiple important initiatives across healthcare preparedness, expanded pharmaceutical
supply chain infrastructure, increased advanced manufacturing, and launched strategic partnerships with U.S. government-focused programs,
achieving the goal of strengthening domestic healthcare resiliency and critical medical supply chains. Management believes the Company’s
rapidly growing pipeline of business opportunities positions it to capitalize on rising demand while executing its plan for growth and
operational excellence.
“We
believe the strongest signal we can send is to invest our own capital at a price that is at a multiple above the current market, but
still at what we perceive to be a discount to the true value of our shares. Investing alongside our shareholders demonstrates our confidence
in the company,” said Christopher Shields, Interim Chief Financial Officer. “We remain focused on disciplined execution and
creating sustainable value for all stakeholders.”
Proceeds
from the investment are expected to support strategic growth initiatives and other corporate objectives that significantly strengthen
the Company’s market position.
Shareholder
Alignment
By
committing personal capital at this level, Callan JMB’s executive leadership is further aligning its interests with those of shareholders.
The investment reinforces management’s total confidence in the Company’s strategic initiatives and its commitment to responsible
stewardship of shareholder capital.
The
shares purchased do not benefit from any registration rights and may only be sold or transferred in accordance with the holding periods
and other conditions prescribed by SEC Rule 144.
About
Callan JMB Inc.
Callan
JMB Inc. (NASDAQ: CJMB) provides logistics, infrastructure, and operational services supporting the healthcare industry, emergency management
agencies, government organizations, and other entities responsible for maintaining essential services. The Company’s capabilities
include product fulfillment, specialty packaging, warehousing, cold-chain logistics, monitoring, regulatory compliance, emergency preparedness,
and response operations. Through continued expansion, Callan JMB is leveraging its expertise in critical infrastructure and supply chain
management to address challenges of national importance.
Investor
Contact
Valter
Pinto
Managing
Director
KCSA
Strategic Communications
CallanJMB@kcsa.com
(212)
896-1254
Media
Contact
Arian
Hopkins
ahopkins@callanjmb.com
Forward-Looking
Statements
This
press release contains “forward-looking statements” within the meaning of applicable federal securities laws. Such statements
include, but are not limited to, statements regarding the Company’s growth strategy, business opportunities, operational expansion,
healthcare preparedness initiatives, manufacturing capabilities, supply chain objectives, expected market demand, strategic partnerships,
workforce development initiatives, and other statements that are not historical facts. These forward-looking statements are based on
current expectations and assumptions and are subject to risks, uncertainties, and other factors that could cause actual results to differ
materially from those expressed or implied. Investors are encouraged to review the Company’s filings with the U.S. Securities and
Exchange Commission for a discussion of factors that could affect future results. The Company undertakes no obligation to update any
forward-looking statements except as required by law.
